Phil Gomez, SIGA Technologies CEO

The mon­key­pox treat­ment and what's com­ing: A con­ver­sa­tion with the CEO mak­ing Tpoxx

Phil Gomez, CEO of Siga Tech­nolo­gies, is hav­ing a busy sum­mer.

His com­pa­ny, which makes the on­ly avail­able mon­key­pox treat­ment, has been prepar­ing for this mo­ment for the last decade, work­ing with a team of sup­pli­ers and ramp­ing up just ahead of the out­break — hop­ing that it would nev­er have to de­ploy its treat­ment.

First ap­proved in 2018 for small­pox, and known as Tpoxx or tecovir­i­mat, the FDA didn’t ini­tial­ly ex­tend the ap­proval to mon­key­pox be­cause the com­pa­ny didn’t run a tri­al pri­or to the cur­rent out­break even though a tri­al could’ve the­o­ret­i­cal­ly been done.

Still, next week, the US plans to ramp up ship­ments of the drug and send out 55,000 dos­es to states and oth­er ju­ris­dic­tions, which is more than dou­ble the cur­rent sup­ply.

So what should peo­ple ex­pect in terms of ac­cess­ing this treat­ment? Is the clin­i­cal tri­al da­ta com­ing? And who’s mak­ing the de­ci­sions around the cur­rent dis­tri­b­u­tion? Read be­low a light­ly edit­ed phone in­ter­view with Gomez from Fri­day morn­ing.

End­points: Can you help me un­der­stand the math bet­ter — if there are about 13,000 con­firmed cas­es by the CDC, and the US says it’s ship­ping out 55,000 dos­es of Tpoxx be­gin­ning next week — shouldn’t every­one who wants the an­tivi­ral get ac­cess to it?

Gomez: I’ll have to de­fer to the CDC and FDA on how they’re do­ing it. It wasn’t clear to me that they’ve changed the cri­te­ria on who would re­ceive the dos­es, and it sound­ed like [they] said they will still fo­cus on pro­vid­ing Tpoxx to high-risk pa­tients. But by pre-po­si­tion­ing more cours­es, they will be able to more rapid­ly get cours­es to pa­tients.

End­points: Is the plan still to ramp up to about 600,000 cours­es of Tpoxx per year, and are you work­ing with con­tract man­u­fac­tur­ers to ramp up pro­duc­tion?

Gomez: There are 1.7 mil­lion dos­es of Tpoxx in the Strate­gic Na­tion­al Stock­pile, so we de­liv­ered those be­gin­ning in 2013, and start­ed de­liv­er­ing more in 2020 — so there is still a sub­stan­tial amount in the SNS. In terms of the CMOs, Siga works with WR Grace and Co. on the ac­tive in­gre­di­ent, Catal­ent for en­cap­su­la­tion, PCI for pack­ag­ing, and Pow­der­size [a Lon­za sub­sidiary] mi­cronizes and tests API for use.

End­points: The NIH next month is about to kick off a place­bo-con­trolled mon­key­pox tri­al in the US, fund­ed and spon­sored by the NIH. Can you talk about Siga’s in­volve­ment in the tri­al?

Gomez: We’re sup­port­ing 10 ran­dom­ized-con­trolled tri­als around the world via gov­ern­ment pub­lic health agen­cies, and we pro­vide drug, place­bo and ex­per­tise, and the good news is these pro­to­cols have been shared broad­ly across the US, Cana­da, UK and EU. So we’re hope­ful wher­ev­er the out­break goes, we’ll have an op­por­tu­ni­ty to rapid­ly col­lect da­ta and file that in the US and Cana­da.

We have ap­proval in the UK and Eu­rope for mon­key­pox, but the NI­AID tri­al would ul­ti­mate­ly al­low us to sup­port a US ap­proval for Tpoxx in mon­key­pox. From a high-lev­el per­spec­tive, these out­pa­tient tri­al pro­to­cols will look at the res­o­lu­tion of symp­toms, with a sec­ondary end­point of re­duc­ing vi­ral load. If any­one pro­gress­es to se­vere dis­ease, they would be un­blind­ed and switched to ac­tive drug.

End­points: How would you com­pare this tri­al to the Covid-19 vac­cine and drug tri­als from ear­li­er in the pan­dem­ic?

Gomez: It’s very dif­fer­ent than a Covid vac­cine tri­al be­cause it’s just look­ing at symp­toms re­solv­ing, which usu­al­ly on­ly last three to four weeks and Tpoxx will po­ten­tial­ly short­en that. With hope­ful­ly hun­dreds en­rolled, these tri­als should be much more rapid than the vac­cine tri­al, but it will de­pend on the out­break and where peo­ple are en­rolled.

End­points: US gov­ern­ment of­fi­cials have dis­trib­uted about 22,000 dos­es of Tpoxx so far. Any idea what the da­ta have shown in terms of the treat­ment work­ing?

Gomez: We haven’t got­ten back any re­al-world ev­i­dence from the CDC yet, so I de­fer to them. Broad­ly, we’ve been ac­tive­ly col­lect­ing da­ta on mon­key­pox, there were da­ta from the UK pub­lished last year, there’s been com­pas­sion­ate use treat­ment in the Cen­tral African Re­pub­lic, and there’s an­oth­er RCT that we’ve set up along­side NI­AID in the De­mo­c­ra­t­ic Re­pub­lic of Con­go be­fore the cur­rent out­break.

The FDA said in 2018 that when we won ap­proval for small­pox, that we couldn’t win one for mon­key­pox per the An­i­mal Rule be­cause we could’ve run a tri­al in the DRC. But the FDA has al­so said the DRC clade is dif­fer­ent from the cur­rent one, so now, with the broad out­break, un­for­tu­nate­ly, the op­por­tu­ni­ty is to col­lect the re­al world da­ta.

End­points: The de­ci­sion to use an ex­pand­ed ac­cess pro­gram to dis­trib­ute Tpoxx — was that a de­ci­sion Siga made? And any plans to move Tpoxx in­to the com­mer­cial mar­ket?

Gomez: The CDC made that de­ci­sion. The drug was de­vel­oped for small­pox and we’ve on­ly ever sold it to gov­ern­ments. So we have not looked at the com­mer­cial sales chan­nels, but we cer­tain­ly now are work­ing to eval­u­ate and plan to put it through the com­mer­cial mar­ket, but that will take time. We’re look­ing at the RCT da­ta as an in­flec­tion point for that.

End­points: Did you push back against the idea of us­ing an ex­pand­ed ac­cess pro­gram to dis­trib­ute Tpoxx?

Gomez: They [the CDC] have the prod­uct in the SNS so they con­trol it. We don’t have a lot of in­put on that.

End­points: And HHS yes­ter­day an­nounced the for­mu­la by which states and ju­ris­dic­tions would be al­lo­cat­ed Tpoxx — did you work with HHS on that for­mu­la?

Gomez: Yes­ter­day was the first time I saw it. The drug is in the SNS. I think we’re viewed more as a sup­pli­er.

End­points: What can you say about the sup­ply and de­mand of Tpoxx world­wide — giv­en that it’s so dif­fi­cult to find in the US, is there a short­age right now? And can you meet the grow­ing de­mand?

Gomez: This is a ques­tion we look at every day. I think most pub­lic health or­ga­ni­za­tions saw the ini­tial out­break and thought it wouldn’t be so dead­ly, so they took a let’s wait-and-see ap­proach. Then in the next phase, as cas­es start­ed to grow, coun­tries bought small sup­plies to treat the cur­rent out­break, and we’ve been work­ing pre­dom­i­nant­ly in that space, and have $60 mil­lion in in­ter­na­tion­al or­ders of prod­uct.

We’re now in the next phase which is where can see this out­break go, and what might we need over the next year or two, and that’s evolv­ing and we have prod­uct avail­able but we don’t know where it will go.

If mil­lions and mil­lions of cours­es are need­ed, we will need to rad­i­cal­ly re­think our sup­ply net­work and ex­pand it. But we just don’t know where it goes.

To pro­vide con­text: In 2020 and 2021, we de­liv­ered about 363,000 cours­es to the US gov­ern­ment, and we an­tic­i­pat­ed de­liv­er­ing that next year and the year af­ter, so we an­tic­i­pat­ed a lot of de­liv­er­ies over the next few years, and we ad­vanced pro­duc­tion of Tpoxx to make sure API was avail­able, so we, for­tu­nate­ly, were in a good place when the out­break hit.

In the fu­ture, there isn’t an ac­tive or­der for oral Tpoxx from BAR­DA but there are two re­main­ing or­ders from a 2018 con­tract and sev­er­al oth­ers for in­tra­venous ver­sions of the drug.

End­points: So if there isn’t a short­age of treat­ments right now, why is it still so dif­fi­cult to get? And why is the gov­ern­ment ret­i­cent to ship out more?

Gomez: That’s a ques­tion for CDC. Dis­tri­b­u­tion is their purview, and there are a lot of com­pli­cat­ed reg­u­la­tions be­cause of the SNS, and the fact that it’s ap­proved for small­pox and not mon­key­pox. We get a lot of ques­tions about use and dos­ing of the drug, and how to give it to chil­dren. For any­one un­der 13 kilo­grams [about 29 pounds], the tablet has to be frac­tion­at­ed, which has been done so far for some chil­dren, and we’re work­ing on a liq­uid re­sus­pen­sion dose that hasn’t been used yet.

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Catal­ent to cut about 200 jobs in Mary­land and Texas

Contract manufacturing company Catalent is cutting about 200 jobs in Maryland and Texas, according to WARN notices, trimming back some of its pandemic-era expansion.

The company will cut 77 jobs by Jan. 15 of next year at a cell therapy facility in Webster, TX, just outside of Houston. In Maryland, the company is reducing staff at two locations, with 82 jobs being eliminated at Catalent’s facility in Gaithersburg, and 53 in Rockville. The layoffs go into effect at those locations on Jan. 14.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

iECURE CEO Joe Truitt and founder Jim Wilson

Jim Wil­son biotech iECURE gets fresh $65M to push pe­di­atric liv­er dis­ease gene ther­a­py in­to the clin­ic

Jim Wilson-founded biotech iECURE has wrapped a $65M Series A extension round to get its lead candidate — a gene replacement therapy for a rare inherited liver disease known as ornithine transcarbamylase deficiency, or OTC — into the clinic.

This round was co-led by Novo Holdings and LYFE Capital, followed by initial investors Versant and OrbiMed as well. In September 2021, iECURE raised a $50 million Series A led by the latter two. The new cash infusion will get iECURE through an initial in-human trial, which CEO Joe Truitt told Endpoints News iECURE hopes to read out in 2024.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Mar­ket­ingRx roundup: Pfiz­er, BioN­Tech re-up iHeartRa­dio hol­i­day spon­sor­ship; WHO re­names mon­key­pox to 'm­pox'

It’s that time of year again for pop music fans with the return of the iHeartRadio Jingle Ball tour — and Pfizer and BioNTech’s sponsorship. For the second year, the Covid-19 vaccine collaborators are the pharma national sponsors among consumer brand partners, including ESPN, Dunkin, M&Ms, Mercedes and Pepsi.

Pfizer and BioNTech are also sponsoring the official Jingle Ball Radio streaming station on iHeart’s network, programmed with music from past and present concert performers. This year they include Lizzo, Dua Lipa, Dove Cameron and Charlie Puth. Pfizer-sponsored radio ads and online video and digital banner ads encourage listeners to get updated Covid-19 booster shots.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Mark Schneider, Nestlé CEO (AP Images)

Nestlé re­con­sid­ers peanut al­ler­gy pro­gram two years af­ter $2.6B buy­out

It seems Nestlé is experiencing some buyer’s remorse two years after throwing down $2.6 billion for Aimmune Therapeutics and its peanut allergy pill Palforzia.

CEO Mark Schneider announced on Tuesday that Nestlé is “exploring strategic options” for Palforzia following lower-than-expected demand. A company spokesperson declined to confirm whether a potential sale is in consideration.

“The review is expected to be completed in the first half of 2023. Going forward, Nestlé Health Science will sharpen its focus on Consumer Care and Medical Nutrition,” the company said in a news release.

Tim Walbert, Horizon Therapeutics CEO (via YouTube)

Hori­zon Ther­a­peu­tics in takeover talks with Am­gen, J&J, Sanofi as po­ten­tial buy­ers

Amgen, J&J’s Janssen and Sanofi are all in talks to acquire Horizon Therapeutics, the rare disease biotech disclosed late Tuesday.

Horizon confirmed “highly preliminary discussions” with those companies regarding a potential buyout offer after the Wall Street Journal reported takeover interest.

Although the company — which commands a market cap of close to $18 billion — emphasized that “there can be no certainty that any offer will be made for the Company,” shares $HZNP still surged 31% in after-hours trading to near $103, bringing it to the point where it started the year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.